Palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine
Cosmetic ingredientCosmetic lipopeptide ingredient
Also known as: Syn-Tacks, Syn-tacks, Syn-tc
Very thin human evidence
- Regulatory standing. Cosmetic ingredient, not regulated as a drug
- Anecdotal. Community reports, no controlled data
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine is a synthetic short peptide attached to a palmitic acid fatty chain, sold to the skincare industry under the trade name Syn-Tacks. The fatty chain is meant to help it interact with skin, and the manufacturer describes it as supporting proteins that anchor the outer skin layer to the layer beneath, which is claimed to relate to skin firmness and wrinkle appearance.
What the evidence shows
It is used as a cosmetic ingredient and is not FDA-approved for any medical use. No registered human trials or published peer-reviewed papers were found, so claims about its effects rest mainly on manufacturer data and remain unverified by independent research.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Sources
- PubChem compound record (CID 72941935)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.